Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.
Jennifer Williams named Vice President, Information Security at HOOPP
Jennifer Williams has been named the new Vice President of Information Security at HOOPP. She brings a wealth of experience and expertise to the role,
